CLENE INC

Insider buying surge at Clene Inc.: Director David Matlin purchases 434k shares, signaling confidence in its neuro‑therapeutic platform and potential upside.

Insider buying surge at Clene (NASDAQ: CLNE) shows executive confidence in its nanotech neurotherapeutics, hinting at potential upside amid market volatility.

Insider sales by Ugwumba Chidozie at Clene Inc. reveal cautious optimism; a significant sell‑off amid rising stock and FDA talks signals potential short‑term dip but long‑term upside if NDA milestones materialize.

Insider sales spike at Clene Inc. reveals cautious optimism—former board member cuts holdings while the company faces negative earnings and liquidity concerns.

Clene insider Ugwumba Chidozie’s recent 4‑month‑wide share sales reveal short‑term liquidity moves, not a confidence drop, amid mixed stock performance and future R&D milestones.

Clene insiders sell 4,278 shares at $4.97—high‑volume trades signal potential undervaluation amid a volatile biotech market; investors weigh risk and buying opportunities.

Clene Inc. insider option grants signal confidence amid volatility—explore why executives bet on a $4.73 strike and what it means for investors.

Clene insider sales reveal cautious strategy: owner sells 3% monthly, hinting at volatility; investors advised to buy on dips and watch for new breakthroughs.

Clene Inc.’s insider sale‑buy strategy shows Mosca’s liquidity shift while holding future upside—insider confidence, FDA milestones, and warrant pricing unveiled.

Insider David Matlin’s big Clene Inc. buy and warrants show confidence in the CNM‑Au8 biomarker’s FDA prospects, offering investors a chance to profit if regulatory milestones spark a rally.